AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

ENTROPY NEURODYNAMICS LIMITED Capital/Financing Update 2020

Nov 8, 2020

64855_rns_2020-11-08_414ec7db-f053-4c75-8acb-a67460fff260.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [595 x 80] intentionally omitted <==

ASX ANNOUNCEMENT

9 November 2020

Notice under Section 708A(5)(E) of the Corporations Act 2001 (Cth)

Exopharm Limited (ASX: EX1) (“Exopharm”, or the “Company”) has today issued 19,873,667 Fully Paid Ordinary Shares; as per the Appendix 2As lodged on 9 November 2020:

Exopharm gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:

1 The aforementioned ordinary shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
2 As at the date of this notice, Exopharm has complied with:
- (a) The provisions of Chapter 2M of the Corporations Act as they apply to Exopharm; and
- (b) Section 674 of the Corporations Act.
3 As at the date of this notice, there is no information that is “excluded information” of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under section 708A(6)(e) of the Corporations Act.

This announcement has been approved for release by the Board.

Sinead Teague Company Secretary Exopharm Limited

EXOPHARM LIMITED ACN: 163 765 991 ASX:EX1 Address: Level 17, 31 Queen Street Melbourne 3000 Telephone: 03 9111 0026 Email: [email protected] Web: www.exopharm.com